Cryoport, Inc. CYRX
20.56 USD -0.18 (-0.87%)
At closeNov 11, 2026, 5:49 PM EST
20.56 0.00 +0.00%
After hours · Nov 11, 5:49 PM ET
20.47 Day range 21.78
7.61 52-week range 21.78
- YTD
- +114.17%
- 1 year
- +132.32%
News
defenseworld.net 93,646 CryoPort, Inc. $CYRX Shares Sold by CenterBook Partners LP CenterBook Partners LP lessened its stake in shares of CryoPort, Inc. (NASDAQ: CYRX) by 54.6% in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange…
seekingalpha.com Cryoport Needs To Chill Down (Downgrade) Cryoport, Inc. is downgraded from Hold to Sell due to valuation concerns despite strong revenue growth. CYRX's balance sheet improved after the CRYOPDP sale, with net cash of $204.8 million, but…
seekingalpha.com Cryoport, Inc. (CYRX) Q3 2026 Earnings Call Transcript Cryoport, Inc. ( CYRX ) Q3 2026 Earnings Call November 5, 2026 5:00 PM EST Company Participants Jerrell Shelton - Chairman, President & CEO Robert Stefanovich - Senior VP, CFO, Treasurer & Chief…
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session Gainers Obsidian Therapeutics (NASDAQ:OBX) stock increased by 27.7% to $12.26 during Friday's regular session. The company's market cap stands at $593.0 million. TransMedics Group (NASDAQ:TMDX)…
benzinga.com Keybanc Maintains Overweight on CryoPort, Raises Price Target to $20 Keybanc analyst Paul Knight maintains CryoPort (NASDAQ:CYRX) with a Overweight and raises the price target from $17 to $20.
benzinga.com Needham Maintains Buy on CryoPort, Raises Price Target to $28 Needham analyst David Saxon maintains CryoPort (NASDAQ:CYRX) with a Buy and raises the price target from $19 to $28.
marketbeat.com CryoPort Q3 Earnings Call Highlights CryoPort NASDAQ: CYRX raised its full-year 2026 revenue outlook after reporting third-quarter revenue growth of 14%, supported by demand for its cell and gene therapy services and cryogenic products.
zacks.com CryoPort, Inc. (CYRX) Reports Q3 Loss, Tops Revenue Estimates CryoPort, Inc. (CYRX) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.18 per share a year ago.
benzinga.com CryoPort Q3 2026 Earnings Call Transcript CryoPort (NASDAQ:CYRX) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…
benzinga.com CryoPort Raises FY2026 Sales Guidance from $192.000M-$196.000M to $197.000M-$199.000M vs $195.441M Est CryoPort (NASDAQ:CYRX) raises FY2026 sales outlook from $192.000 million-$196.000 million to $197.000 million-$199.000 million vs $195.441 million estimate.- benzinga.com CryoPort Q3 EPS $(0.25) Misses $(0.18) Estimate, Sales $50.220M Beat $48.828M Estimate CryoPort (NASDAQ:CYRX) reported quarterly losses of $(0.25) per share which missed the analyst consensus estimate of $(0.18) by 38.89 percent. This is a 38.89 percent decrease over losses of $(0.18)…
prnewswire.com Cryoport Reports Third Quarter 2026 Financial Results Third quarter revenue grew 14% year-over-year to $50.2 million Commercial Cell and Gene Therapy revenue increased 20% year-over-year Supporting a record 788 global clinical trials and 23 commercially…
seekingalpha.com Conestoga Micro Cap Composite: Q3 2026 Leaders, Laggards, Buys And Sells We remain encouraged by the operational performance of the Micro cap companies held in portfolios. TWST shares surged as a strong fiscal 3Q highlighted accelerating demand across several of the…
prnewswire.com Cryoport to Report Third Quarter 2026 Financial Results on November 5, 2026 NASHVILLE, Tenn., Oct. 22, 2026 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for…
benzinga.com CryoPort Q2 2026 Earnings Call Transcript CryoPort (NASDAQ:CYRX) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. This transcript is brought to you by Benzinga APIs. For real-time…- benzinga.com BTIG Maintains Buy on CryoPort, Raises Price Target to $26 BTIG analyst David Larsen maintains CryoPort (NASDAQ:CYRX) with a Buy and raises the price target from $25 to $26.
zacks.com Is CryoPort (CYRX) Outperforming Other Medical Stocks This Year? Here is how CryoPort, Inc. (CYRX) and Delcath Systems, Inc. (DCTH) have performed compared to their sector so far this year.
benzinga.com Guggenheim Maintains Buy on CryoPort, Raises Price Target to $19 Guggenheim analyst Subbu Nambi maintains CryoPort (NASDAQ:CYRX) with a Buy and raises the price target from $16 to $19.
seekingalpha.com Cryoport: Strong Pipeline Of Cell And Gene Therapy Approvals Cryoport, Inc., rated BUY, is up 82% YTD, driven by robust cell and gene therapy (CGT) commercialization and pipeline momentum. CYRX returned to adjusted EBITDA profitability in 2Q26, with strong…
zacks.com CryoPort (CYRX) Upgraded to Buy: Here's Why CryoPort (CYRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
seekingalpha.com Cryoport, Inc. (CYRX) Q2 2026 Earnings Call Transcript Cryoport, Inc. (CYRX) Q2 2026 Earnings Call Transcript
benzinga.com Guggenheim Maintains Buy on CryoPort, Raises Price Target to $16 Guggenheim analyst Subbu Nambi maintains CryoPort (NASDAQ:CYRX) with a Buy and raises the price target from $12 to $16.
benzinga.com Needham Maintains Buy on CryoPort, Raises Price Target to $19 Needham analyst David Saxon maintains CryoPort (NASDAQ:CYRX) with a Buy and raises the price target from $15 to $19.
marketbeat.com CryoPort Q2 Earnings Call Highlights CryoPort NASDAQ: CYRX reported second-quarter 2026 revenue of $49 million and said it reached positive adjusted EBITDA from continuing operations, while reaffirming its full-year revenue outlook of…
zacks.com CryoPort, Inc. (CYRX) Reports Q2 Loss, Beats Revenue Estimates CryoPort, Inc. (CYRX) came out with a quarterly loss of $0.2 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.29 per share a year ago.- benzinga.com Conference Call:
CryoPort Affirms FY2026 Sales Guidance of $192.000M-$196.000M vs $194.390M Est CryoPort (NASDAQ:CYRX) affirms FY2026 sales outlook from $192.000 million-$196.000 million to $192.000 million-$196.000 million vs $194.390 million estimate.
- benzinga.com CryoPort Q2 Adj. EPS $(0.20) Misses $(0.19) Estimate, Sales $48.971M Beat $48.207M Estimate CryoPort (NASDAQ:CYRX) reported quarterly losses of $(0.20) per share which missed the analyst consensus estimate of $(0.19) by 5.26 percent. This is a 16.67 percent increase over losses of $(0.24)…
prnewswire.com Cryoport Reports Second Quarter 2026 Financial Results Second quarter revenue grew 8% year-over-year to $49.0 million Life Sciences Services revenue increased 15% year-over-year BioStorage/BioServices revenue grew 25% year-over-year Supporting 779 global…- benzinga.com BTIG Maintains Buy on CryoPort, Raises Price Target to $25 BTIG analyst David Larsen maintains CryoPort (NASDAQ:CYRX) with a Buy and raises the price target from $17 to $25.
prnewswire.com Cryoport to Report Second Quarter 2026 Financial Results on August 6, 2026 NASHVILLE, Tenn., July 23, 2026 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for…
benzinga.com Cryoport’s IntegriCell Cryopreservation Services Selected By Verismo Therapeutics To Support SynKIR-110 And SynKIR-310 Multi-Chain KIR-CAR Programs IntegriCell Provides Process Development, Technology Transfer, and Clinical Cryopreservation Services Supporting Verismo's Novel Multi-chain KIR-CAR Programs for Lead Candidates SynKIR™-110 and…
prnewswire.com Cryoport's IntegriCell® Cryopreservation Services Selected by Verismo Therapeutics to Support Clinical KIR-CAR T Cell Therapy Programs IntegriCell Provides Process Development, Technology Transfer, and Clinical Cryopreservation Services Supporting Verismo's Novel Multi-chain KIR-CAR Programs for Lead Candidates SynKIR™-110 and…- benzinga.com Craig-Hallum Maintains Buy on CryoPort, Raises Price Target to $20 Craig-Hallum analyst Matthew Hewitt maintains CryoPort (NASDAQ:CYRX) with a Buy and raises the price target from $15 to $20.
- benzinga.com Keybanc Maintains Overweight on CryoPort, Raises Price Target to $17 Keybanc analyst Paul Knight maintains CryoPort (NASDAQ:CYRX) with a Overweight and raises the price target from $15 to $17.
- benzinga.com Guggenheim Maintains Buy on CryoPort, Raises Price Target to $12 Guggenheim analyst Subbu Nambi maintains CryoPort (NASDAQ:CYRX) with a Buy and raises the price target from $11 to $12.
benzinga.com Needham Maintains Buy on CryoPort, Raises Price Target to $15 Needham analyst David Saxon maintains CryoPort (NASDAQ:CYRX) with a Buy and raises the price target from $13 to $15.
benzinga.com BTIG Maintains Buy on CryoPort, Raises Price Target to $17 BTIG analyst David Larsen maintains CryoPort (NASDAQ:CYRX) with a Buy and raises the price target from $15 to $17.
seekingalpha.com Cryoport, Inc. (CYRX) Q1 2026 Earnings Call Transcript Cryoport, Inc. (CYRX) Q1 2026 Earnings Call Transcript
zacks.com CryoPort, Inc. (CYRX) Reports Q1 Loss, Tops Revenue Estimates CryoPort, Inc. (CYRX) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.2. This compares to a loss of $0.22 per share a year ago.
benzinga.com Cryoport Posts Revenue Beat In Q1 As Clinical Trial Support Hits All-Time High — 'A Strong Start To 2026' Cryoport released financial results for Q1 of fiscal 2026 Monday after the closing bell.- benzinga.com CryoPort Raises FY2026 Sales Guidance from $190.000M-$194.000M to $192.000M-$196.000M vs $191.834M Est CryoPort (NASDAQ:CYRX) raises FY2026 sales outlook from $190.000 million-$194.000 million to $192.000 million-$196.000 million vs $191.834 million estimate.
- benzinga.com CryoPort Q1 Adj. EPS $(0.25) Misses $(0.22) Estimate, Sales $47.800M Beat $44.862M Estimate CryoPort (NASDAQ:CYRX) reported quarterly losses of $(0.25) per share which missed the analyst consensus estimate of $(0.22) by 13.64 percent. This is a 10.71 percent increase over losses of $(0.28)…
prnewswire.com Cryoport Reports First Quarter 2026 Financial Results First quarter revenue grew 16% year-over-year to $47.8 million Commercial cell and gene therapy (CGT) revenue grew 26% year-over-year to $9.1 million, reflecting continued expansion in approved CGT…
benzinga.com Earnings Scheduled For May 4, 2026 - benzinga.com Craig-Hallum Initiates Coverage On CryoPort with Buy Rating, Announces Price Target of $15 Craig-Hallum analyst Matthew Hewitt initiates coverage on CryoPort (NASDAQ:CYRX) with a Buy rating and announces Price Target of $15.
benzinga.com Semtech To Rally Around 28%? Here Are 10 Top Analyst Forecasts For Wednesday Wall Street analysts changed outlook on top names. For full view of changes, including upgrades/downgrades, see analyst ratings page.- benzinga.com Needham Maintains Buy on CryoPort, Raises Price Target to $13 Needham analyst David Saxon maintains CryoPort (NASDAQ:CYRX) with a Buy and raises the price target from $12 to $13.
benzinga.com CryoPort Q4 Earnings Summary & Key Takeaways - benzinga.com Earnings Scheduled For March 3, 2026
benzinga.com Ryvyl, NeoGenomics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session